PORTFOLIO NEWS Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million September 17, 2024 Read More » Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate September 10, 2024 Read More » Kallyope Announces License Agreement with Novo Nordisk September 10, 2024 Read More » Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion September 4, 2024 Read More » Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies September 3, 2024 Read More » ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates August 12, 2024 Read More » Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer August 12, 2024 Read More » Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 8, 2024 Read More » RAPT Therapeutics Reports Second Quarter 2024 Financial Results August 8, 2024 Read More » Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease August 7, 2024 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million September 17, 2024 Read More »
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate September 10, 2024 Read More »
Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion September 4, 2024 Read More »
Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies September 3, 2024 Read More »
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates August 12, 2024 Read More »
Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer August 12, 2024 Read More »
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 8, 2024 Read More »
Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease August 7, 2024 Read More »
